Treace Medical Concepts (TMCI) Cash & Equivalents (2020 - 2026)

Treace Medical Concepts (TMCI) has reported Cash & Equivalents for 7 consecutive years, with $12.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 56.61% year-over-year to $12.6 million; the trailing twelve-month figure through Jun 2026 stood at $12.6 million (up 56.61% YoY), and the FY2025 full-year result was $10.7 million, down 5.66% from the prior year.
• Cash & Equivalents advanced to $12.6 million in Q2 2026 per TMCI's latest filing, from $9.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $101.5 million in Q2 2022 and bottomed at $7.3 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $26.8 million across 5 years, with a median of $12.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 507.25% in 2022, then slumped 91.78% in 2023.
• Over 5 years, Cash & Equivalents stood at $19.5 million in 2022, then slumped by 33.33% to $13.0 million in 2023, then dropped by 12.57% to $11.4 million in 2024, then fell by 5.66% to $10.7 million in 2025, then rose by 17.76% to $12.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $12.6 million, $9.5 million, and $10.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.